THE EU said today it had given the green light for US pharmaceutical giant Pfizer’s US$43 billion (RM204.25 billion) acquisition of biotech firm Seagen that specialised in innovative cancer treatment.  

The European Commission, the bloc’s powerful anti-trust authority, said it had “unconditionally approved” the transaction after a market investigation.